Report Description Table of Contents How Are New Cancer Therapy Approvals, Clinical Advances, and Expanding Treatment Access Shaping the Global Oncolytic Virus Immunotherapy Market? – (Updated On: 29th-Oct-2026) According to Strategic Market Research, the Global Oncolytic Virus Immunotherapy Market was valued at USD 122.82 million in 2025 and is projected to reach USD 602.00 million by 2032, expanding at a CAGR of 25.49% during 2026–2032. The projected USD 479.18 million increase in annual market revenue is supported by new regulatory approvals, growing demand for treatment options in immunotherapy-resistant cancers, and clinical development of oncolytic viruses for melanoma, glioma, lung cancer, and other solid tumors. These therapies use modified viruses to selectively attack cancer cells and stimulate antitumor immune responses, with growing commercial interest in their combination with checkpoint inhibitors. Clinical evidence demonstrates the potential of oncolytic virus therapies, particularly in combination cancer treatment. A 2026 systematic review published in the Journal of Evidence-Based Medicine examined 188 clinical trials involving 5,410 patients, including 1,586 melanoma patients (29.3%). Among patients evaluated for efficacy, the overall response rate was 24.6%, while disease control was reported in 59.1%. Combination treatments achieved a 31.8% response rate, compared with 17.3% for oncolytic virus monotherapy, highlighting opportunities for combination regimens. These pooled findings cover different cancers and treatment protocols rather than a direct randomized comparison. Approved oncolytic virus therapies have established clinical benchmarks and are expanding treatment options. The pioneering melanoma therapy Imlygic (T-VEC) demonstrated a 16.3% durable response rate versus 2.1% with GM-CSF, alongside an overall response rate of 26.4% versus 5.7%. In August 2026, the U.S. FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma progressing after anti-PD-1 therapy. The supporting trial enrolled 140 patients, with a 24.2% response rate among 91 efficacy-evaluable patients and a median response duration of 14.1 months. Continued approval requires confirmation of clinical benefit. Early commercialization is demonstrating demand for newly approved oncolytic immunotherapies in the United States. According to Replimune's October 28, 2026 update, Tudriqev was first delivered to patients on October 6, 2026, and more than 15 U.S. healthcare institutions had prescribed the therapy. The company had engaged over 70% of its initial 200 priority healthcare accounts and estimated approximately 10,000 potentially eligible U.S. patients. These figures indicate an emerging commercial opportunity among patients with treatment-resistant melanoma, with uptake dependent on clinical adoption, reimbursement, and treatment-center readiness. The international market is expanding through established approvals and cancer-specific clinical development. China pioneered commercial oncolytic virotherapy with approval of Oncorine (H101) in 2005 for certain head and neck cancers, while Imlygic gained approval in the United States and Europe and Delytact established a treatment pathway for malignant glioma in Japan. Clinical programs involving CAN-2409, cretostimogene, and other investigational viral therapies are exploring additional cancer indications. Notably, Adstiladrin, approved for BCG-unresponsive bladder cancer, is a non-replicating viral gene therapy rather than an oncolytic virus and represents an adjacent therapeutic category. The Global Oncolytic Virus Immunotherapy Market is entering a new commercialization phase, supported by improved clinical evidence, expanded melanoma treatment options, and combination immunotherapy development. The United States represents an important near-term revenue opportunity following Tudriqev's approval, while China and Japan provide established regional foundations for virus-based cancer treatments. Through 2032, market expansion will depend on successful confirmatory trials, broader cancer indications, insurance coverage, and sustained adoption across specialized oncology centers. Which Subsegments Are Leading the Oncolytic Virus Immunotherapy Market and Which Offer the Strongest Expansion Opportunities? By Virus Type: Engineered Platforms Broaden Tumor-Selective Treatment Leading Subsegment: Herpes Simplex Virus (HSV) Herpes Simplex Virus (HSV) leads the global Oncolytic Virus Immunotherapy Market, accounting for 43% of the market, valued at approximately USD 52.81 million in 2025, and is projected to grow at a CAGR of 23.20% during 2026–2032. HSV-1 serves as a genetically engineered oncolytic platform that selectively infects and destroys malignant cells while stimulating antitumor immune responses. Its ability to convert immunologically cold tumors into immune-responsive targets, alongside established clinical applications in melanoma and ongoing research across solid tumors, reinforces its market leadership. Fastest-Growing Subsegment: Vaccinia Virus Vaccinia virus-based immunotherapy accounted for an estimated 18% of the global Oncolytic Virus Immunotherapy Market in 2025, representing USD 22.11 million, and is projected to achieve the fastest CAGR of 28.00% during 2026–2032. Vaccinia virus (VACV) selectively targets and destroys malignant cells while stimulating antitumor immune responses by transforming immunosuppressive tumor microenvironments into immunologically active sites. Its capacity to accommodate therapeutic gene modifications, enhance immune-cell infiltration, and support combination treatments with immune checkpoint inhibitors is accelerating clinical development across solid tumor indications. By Therapy Type: Combination Regimens Target Treatment Resistance Leading Subsegment: Monotherapy Monotherapy represents a leading treatment approach in the global Oncolytic Virus Immunotherapy Market, accounting for an estimated 58% market share, valued at USD 71.24 million in 2025, with a projected CAGR of 20.65% during 2026–2032. Monotherapy involves administering a single natural or genetically modified oncolytic virus to selectively destroy cancer cells while stimulating antitumor immune responses. Its market leadership is supported by advancements in viral engineering, growing clinical evaluation of standalone oncolytic therapies, and increasing interest in targeted cancer treatments with improved therapeutic specificity. Fastest-Growing Subsegment: Combination Therapy Combination therapy leads the global Oncolytic Virus Immunotherapy Market with an estimated 42% market share, representing USD 51.58 million in 2025, and is projected to register the fastest CAGR of 30.75% during 2026–2032. Its leadership is supported by the ability of oncolytic viruses to transform immunologically “cold,” treatment-resistant tumors into “hot,” immune-active tumor microenvironments, enhancing antitumor immune responses. Combining oncolytic viruses with immune checkpoint inhibitors, chemotherapy, or radiotherapy offers opportunities to improve therapeutic efficacy, strengthen immune activation, and expand clinical applications across multiple cancer types. By Cancer Type: Established Melanoma Use Supports Broader Tumor Development Leading Subsegment: Melanoma Melanoma dominates the global Oncolytic Virus Immunotherapy Market, accounting for an estimated 48% market share, equivalent to USD 58.95 million in 2025, and is projected to expand at a CAGR of 21.47% during 2026–2032. Its leadership is supported by the clinical application of oncolytic viruses in advanced melanoma, where they selectively infect and destroy malignant cells while stimulating systemic antitumor immune responses. The established clinical use of talimogene laherparepvec (T-VEC) and ongoing investigations involving immune checkpoint inhibitor combinations further strengthen melanoma's position in oncolytic virotherapy. Fastest-Growing Subsegment: Lung Cancer Lung cancer represents an estimated 17% share of the global Oncolytic Virus Immunotherapy Market, equivalent to USD 20.88 million in 2025, and is projected to record the fastest CAGR of 30.47% during 2026–2032. Oncolytic virus immunotherapy utilizes genetically engineered or naturally occurring viruses to selectively infect, replicate within, and destroy lung cancer cells while stimulating systemic antitumor immune responses. Growing clinical investigation of viral immunotherapies, particularly in combination with immune checkpoint inhibitors for non-small cell lung cancer, is supporting therapeutic innovation and commercial opportunities. By Route of Administration: Localized Injection and Systemic Delivery Shape Clinical Reach Leading Subsegment: Intratumoral Administration Intratumoral administration plays a dominant role in the Oncolytic Virus Immunotherapy Market, accounting for an estimated 84% market share, valued at USD 103.17 million in 2025, with a projected CAGR of 24.23% during 2026–2032. Direct injection of oncolytic viruses into tumor tissue enables selective cancer cell destruction, promotes tumor-associated antigen release, and stimulates localized immune responses. Its ability to transform immunologically inactive “cold” tumors into immune-responsive “hot” tumors strengthens its clinical significance, particularly in melanoma and other accessible solid tumors. Fastest-Growing Subsegment: Intravenous Administration Intravenous (IV) administration is emerging as a rapidly expanding delivery route in the Oncolytic Virus Immunotherapy Market, accounting for an estimated 16% market share, equivalent to USD 19.65 million in 2025, and is projected to register the fastest CAGR of 31.13% during 2026–2032. Intravenous delivery enables systemic distribution of oncolytic viruses, supporting therapeutic targeting of widespread and metastatic cancer lesions beyond the reach of direct intratumoral injection. Advancements in viral engineering, immune evasion strategies, and tumor-selective delivery are strengthening its potential in systemic cancer immunotherapy. By End User: Specialized Oncology Infrastructure Supports Treatment Translation Leading Subsegment: Hospitals Hospitals lead the end-user category in the Oncolytic Virus Immunotherapy Market, accounting for an estimated 64% market share, equivalent to USD 78.60 million in 2025, with a projected CAGR of 23.79% during 2026–2032. Their leadership reflects the availability of specialized oncology infrastructure, multidisciplinary cancer care teams, and established protocols for administering virus-based immunotherapies. Hospitals also play a central role in patient monitoring, treatment safety, and clinical trials, supporting the integration of oncolytic virus therapies into advanced cancer treatment programs worldwide. Fastest-Growing Subsegment: Research Institutes Research institutes play a critical role in advancing the oncolytic virus immunotherapy market through viral genetic engineering, tumor-selective virus development, preclinical investigations, and clinical translation. Research institutes accounted for an estimated 9% market share, representing USD 11.05 million in 2025, and are projected to register the fastest CAGR of 28.59% during 2026–2032. Expanding research into virus-mediated tumor destruction, immune system activation, and combination immunotherapies is accelerating experimental breakthroughs, strengthening academic-industry collaborations, and supporting the development of next-generation oncolytic viral therapies. By Geography: Regulatory Pathways and Biotechnology Investment Shape Adoption Leading Region: North America North America leads the global Oncolytic Virus Immunotherapy Market, accounting for an estimated 44% market share, valued at USD 54.04 million in 2025, with a projected CAGR of 23.21% during 2026–2032. Regional leadership is supported by the clinical adoption of FDA-approved talimogene laherparepvec (T-VEC, marketed as Imlygic) for eligible patients with advanced melanoma. The United States remains central to market expansion, supported by established oncology infrastructure, ongoing clinical trials, and increasing research investments in oncolytic viral therapies and combination immunotherapy approaches. Fastest-Growing Region: Asia-Pacific Asia-Pacific oncolytic virus immunotherapy market is gaining significant momentum, supported by expanding cancer immunotherapy research, clinical trials, and investment in advanced biotherapeutics. The region accounted for an estimated 24% of the global market in 2025, representing USD 29.48 million, and is projected to register the fastest regional CAGR of 29.91% during 2026–2032. China, Japan, and South Korea are advancing virus-based cancer treatment development through expanding biotechnology capabilities, supportive regulatory initiatives, and growing clinical interest in targeted immuno-oncology therapies. Which Emerging Therapies Are Transforming the Oncolytic Virus Immunotherapy Market? 1. Herpes Simplex Virus-Based Immunotherapies Engineered herpes simplex virus (HSV) therapies represent an important advancement in tumor-selective viral treatment, particularly for advanced melanoma, glioblastoma, and other treatment-resistant malignancies. These therapies use genetically modified HSV platforms to destroy cancer cells while stimulating antitumor immune activity. Replimune's RP1 (vusolimogene oderparepvec) combines engineered HSV-1 technology with GM-CSF expression and enhanced viral activity to support tumor destruction and immune activation. Its development alongside nivolumab focuses on advanced melanoma, while RP2 incorporates an anti-CTLA-4 mechanism and is being investigated in additional solid tumors. These technologies offer opportunities to expand viral immunotherapy into patients with limited responses to existing treatments. 2. Adenovirus-Based Oncolytic Therapies Genetically engineered adenoviruses are gaining clinical importance in bladder cancer treatment, particularly for patients with non-muscle-invasive bladder cancer that does not respond adequately to Bacillus Calmette-Guérin (BCG) therapy. CG Oncology's cretostimogene grenadenorepvec uses a selectively replicating adenovirus designed to destroy malignant bladder cells through intravesical administration. Its clinical development includes the BOND-003 and PIVOT-006 programs, targeting bladder preservation and improved local disease control. This approach creates potential commercial opportunities within urology departments, specialized cancer centers, and outpatient oncology facilities. 3. Oncolytic Virus and Checkpoint Inhibitor Combinations Combination immunotherapy is emerging as an important strategy for overcoming resistance to existing cancer treatments. Oncolytic viruses can promote tumor antigen release and immune-cell recruitment, while checkpoint inhibitors help sustain immune responses against malignant cells. Replimune's RP2, incorporating an anti-CTLA-4 antibody mechanism, is being investigated alongside nivolumab, a PD-1 checkpoint inhibitor. Similarly, investigational viral platforms are being evaluated in combination with established immunotherapies across melanoma, lung cancer, and other solid tumors. Successful clinical outcomes could support broader treatment applications and pharmaceutical collaboration opportunities. 4. Next-Generation Immune-Engineered Viral Platforms Multifunctional viral platforms are expanding the therapeutic capabilities of oncolytic immunotherapy by incorporating genes that produce immune-activating proteins directly within tumor environments. The investigational OH2 and BS006 combination illustrates this approach. OH2 is an HSV-2-based virus engineered to express GM-CSF, while BS006 is designed to deliver a PD-L1/CD3 bispecific antibody that redirects T-cell activity toward cancer cells. These platforms could improve localized immune activation and enable differentiated treatment strategies for advanced solid tumors. 5. Systemically Delivered Reovirus Immunotherapies Systemic reovirus therapy offers an opportunity to treat metastatic cancers through intravenous administration, potentially reaching multiple tumor sites without requiring direct injections into every lesion. Oncolytics Biotech's pelareorep uses a naturally occurring reovirus platform investigated for its tumor-killing and immune-stimulating properties. Its combination development in breast cancer and other solid tumors could expand the commercial scope of viral immunotherapy. Clinical success would support opportunities in oncology centers treating patients with widespread disease. 6. Advanced Glioblastoma-Targeted Viral Therapies Oncolytic viral immunotherapy is also advancing in malignant brain tumors, where treatment resistance and limited therapeutic options create significant clinical needs. Daiichi Sankyo's Delytact (teserpaturev/G47Δ) is an engineered HSV-1 therapy that received conditional and time-limited approval in Japan in June 2021 for malignant glioma. The therapy demonstrates the clinical potential of locally administered viral platforms in neuro-oncology and provides an important precedent for investigating treatments for glioblastoma. Which Companies Are Leading Innovation and Commercialization in the Oncolytic Virus Immunotherapy Market? Amgen — Commercial Leadership in HSV-Based Viral Immunotherapy Amgen established an important commercial foundation for the market through Imlygic (talimogene laherparepvec or T-VEC), an engineered herpes simplex virus type 1 therapy approved by the U.S. FDA on October 27, 2015 for local treatment of selected unresectable melanoma lesions. The therapy uses genetically modified HSV-1 technology to replicate within tumors and express GM-CSF, promoting immune activation. In its pivotal clinical investigation, Imlygic demonstrated a 16.3% durable response rate compared with 2.1% for GM-CSF treatment, establishing evidence for the therapeutic application of oncolytic viruses. Amgen's experience in viral manufacturing, regulated biologic production, and oncology commercialization provides an important competitive advantage in established treatment delivery. Replimune Group Inc. — Next-Generation HSV Immunotherapy and Combination Treatment Replimune specializes in engineered HSV-based immunotherapies designed to combine direct tumor destruction with immune system stimulation. Its principal therapy, TUDRIQEV (RP1; vusolimogene oderparepvec), received FDA accelerated approval on August 6, 2026, in combination with nivolumab for certain patients with advanced cutaneous melanoma following anti-PD-1 therapy. The pivotal IGNYTE study enrolled 140 patients, including 91 efficacy-evaluable patients with noninjected lesions. Among these 91 patients, treatment achieved a 24.2% objective response rate, with a median response duration of 14.1 months. Replimune is also developing RP2, incorporating anti-CTLA-4 functionality, for additional solid tumor indications. The approved combination provides an important commercial opportunity, while the Phase 3 IGNYTE-3 trial is intended to confirm clinical benefit. CG Oncology — Advanced Adenovirus Technology for Bladder Cancer CG Oncology is a prominent clinical-stage developer advancing cretostimogene grenadenorepvec, a genetically modified adenovirus designed for intravesical treatment of non-muscle-invasive bladder cancer. Its tumor-selective viral technology targets malignant bladder cells while offering a potential bladder-preserving alternative for patients whose disease remains unresponsive to BCG therapy. According to the company's July 2026 report of Phase 3 BOND-003 results, 75.5% of evaluated patients achieved a complete response at some point during treatment, while the estimated 24-month duration-of-response rate reached 60.1%. The company also reported that 96.6% of patients remained free from progression to muscle-invasive bladder cancer at 96 weeks. These findings support further regulatory development and demonstrate opportunities for viral therapies in specialized urologic oncology services. Other Notable Companies and Their Roles: Oncolytics Biotech Inc. — Develops pelareorep, an intravenously administered reovirus-based immunotherapy being investigated with chemotherapy and checkpoint inhibitors for colorectal, pancreatic, and anal cancers. Genelux Corporation — Advances Olvi-Vec, an engineered vaccinia virus undergoing Phase 3 investigation through the OnPrime program for platinum-resistant or refractory ovarian cancer, supporting viral immunochemotherapy development. Transgene S.A. — Applies viral-vector engineering to cancer immunotherapy, with experience in modified vaccinia platforms and development of individualized neoantigen vaccines through its myvac technology. Targovax (formerly, now associated with Circio Holding) — Historically developed ONCOS-102, a GM-CSF-expressing oncolytic adenovirus investigated for solid tumors; Circio subsequently shifted its strategic focus toward circular RNA technologies Analyst Commentary: How Will Durable Responses and Scalable Manufacturing Shape Commercial Success? The oncolytic virus immunotherapy market is entering a critical commercialization phase, where clinical efficacy, durable patient responses, and regulatory approvals will determine long-term success. The strongest opportunities lie in expanding viral therapies beyond melanoma into high-unmet-need solid tumors, improving systemic delivery, and integrating oncolytic viruses with checkpoint inhibitors. Investment priorities are shifting toward advanced viral engineering, scalable manufacturing, and late-stage clinical validation. Wider adoption will depend on demonstrating meaningful survival benefits, securing reimbursement, and establishing these therapies within standard oncology treatment pathways. Oncolytic Virus Immunotherapy Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 122.82 Million Revenue Forecast in 2032 USD 602.00 Million Overall Growth Rate CAGR of 25.49% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Virus Type, By Therapy Type, By Cancer Type, By Route of Administration, By End User, By Geography By Virus Type Herpes Simplex Virus (HSV), Adenovirus, Vaccinia Virus, Others By Therapy Type Monotherapy, Combination Therapy By Cancer Type Melanoma, Glioblastoma, Lung Cancer, Others By Route of Administration Intratumoral Administration, Intravenous Administration By End User Hospitals, Specialty Cancer Centers, Research Institutes By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Expansion of approved viral immunotherapies, development of combinations with checkpoint inhibitors, treatment requirements in immunotherapy-resistant cancers, clinical research across additional solid tumors, investment in viral engineering and manufacturing capacity Customization Option Available upon request Frequently Asked Question About This Report Q1. Why are companies investing in combination treatments in the market? A1. Combining viral therapies with checkpoint inhibitors offers a potential way to address treatment-resistant cancers. Developers are seeking stronger and more durable responses than either approach may achieve alone. Successful programs could expand eligible patient populations and create pharmaceutical partnership opportunities. Q2. Which cancer application holds the largest market share? A2. Melanoma leads with an estimated 48% share in 2025. Its position reflects established treatment experience and continued development of engineered viral therapies. Expansion into other cancers remains an important opportunity, but depends on indication-specific clinical evidence and regulatory outcomes. Q3. How could delivery innovations influence industry growth? A3. Intravenous delivery could broaden treatment options for tumors that are difficult to inject directly. Developers are investigating ways to reach multiple tumor sites while maintaining safety and effectiveness. Clinical validation will determine whether systemic approaches can expand use beyond accessible lesions. Q4. What are the main challenges affecting market expansion? A4. Developers must demonstrate durable clinical benefit and confirm promising results in larger trials. Commercial uptake also depends on reimbursement and treatment-center readiness. Reliable manufacturing and specialized administration capabilities are important to translating approvals into sustained patient access. Q5. How are companies differentiating their platforms in the industry? A5. Companies are developing different viral platforms for specific cancers and treatment settings. Amgen and Replimune focus on engineered herpesvirus approaches, while CG Oncology is advancing an adenovirus program for bladder cancer. Differentiation depends on response durability, delivery requirements and clinical positioning. Sources: U.S. FDA – Imlygic’s Pivotal Trial Randomized 436 Patients and Demonstrated a 16.3% Durable Response Rate Compared With 2.1% for GM-CSF FDA – Imlygic Prescribing Information: Melanoma Patient Enrollment and Clinical Results Amgen – Imlygic Achieved a 26.4% Overall Response Rate Versus 5.7% With GM-CSF in the Pivotal Melanoma Study, Supporting Its Established Position in HSV-Based Oncolytic Immunotherapy Amgen – Imlygic European Approval and OPTiM Phase III Clinical Outcomes European Medicines Agency – Imlygic Received EU Marketing Authorization on December 16, 2015, for Selected Adults With Unresectable Melanoma Without Bone, Brain, Lung, or Other Visceral Disease EMA – Imlygic: Authorized Indication, Regulatory History, and Product Information U.S. FDA – Tudriqev Received Accelerated Approval on August 6, 2026, With Nivolumab for Advanced Cutaneous Melanoma Progressing After Anti-PD-1 Therapy; Response Rate Was 24.2% Among 91 Efficacy-Evaluable Patients From a 140-Patient Trial FDA – Tudriqev Approval: IGNYTE Patient Population, Response Rate, and Median Response Duration of 14.1 Months U.S. FDA – Tudriqev’s Confirmatory IGNYTE-3 Trial Is Required to Evaluate Overall Survival, With Approximately 400 Patients Planned for Randomization and a Listed Completion Requirement of March 2031 FDA – Ongoing Cancer Accelerated Approvals: Tudriqev Confirmatory Trial Obligations Replimune – October 28, 2026 Update Reported First Commercial Patient Deliveries of Tudriqev on October 6 and Prescriptions From More Than 15 Institutions, Providing Early Evidence of U.S. Commercial Adoption Replimune – Fiscal Second Quarter 2027 Results and Tudriqev Commercial Launch Update Daiichi Sankyo – Delytact Received Conditional and Time-Limited Approval in Japan on June 11, 2021, for Malignant Glioma, Establishing a Regional Commercial Pathway for Oncolytic Brain Cancer Therapy Daiichi Sankyo – Delytact Oncolytic Virus G47Δ Approved in Japan for Malignant Glioma Japan Pharmaceuticals and Medical Devices Agency – Delytact’s Supporting Study Included 19 Patients Who Received at Least One Dose; Authorized Administration Allows Up to Six Intratumoral Doses PMDA – Delytact Regulatory Review: Treated Patient Counts, Clinical Evidence, and Administration Requirements CG Oncology – BOND-003 Cohort C Reported Complete Responses in 75.5% of 110 Evaluable Patients, With an Estimated 24-Month Duration-of-Response Rate of 60.1% for Investigational Cretostimogene CG Oncology – Phase III BOND-003 Results in High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Genelux – August 2026 Update Confirmed Ongoing Phase III OnPrime Development of Olvi-Vec in Platinum-Resistant or Refractory Ovarian Cancer, Alongside Systemic Administration Studies in Small-Cell and Non-Small-Cell Lung Cancer Genelux – Second Quarter 2026 Results: Olvi-Vec Ovarian and Lung Cancer Development Programs Oncolytics Biotech – October 14, 2026 Update Reported That Investigational Intravenous Pelareorep Had Been Administered to More Than 1,200 Patients Across Clinical Development, With GOBLET Follow-Up Continuing in Anal and Pancreatic Cancer Oncolytics Biotech – Pelareorep Patient Exposure and October 2026 GOBLET Development Update Oncolytics Biotech – March 2026 Announcement Introduced the Randomized Phase II REO 033 Colorectal Cancer Study, With Planned Enrollment of 30 Patients Per Arm to Evaluate Adding Pelareorep to Bevacizumab and FOLFIRI Oncolytics Biotech – Randomized Pelareorep Study in RAS-Mutated, Microsatellite-Stable Metastatic Colorectal Cancer. Candel Therapeutics – March 2026 Update Reported FDA IND Clearance for CAN-3110, an Investigational HSV-Based Oncolytic Therapy for Recurrent High-Grade Glioma, Supporting Further Clinical Development Candel Therapeutics – 2026 Corporate Update: CAN-3110 Regulatory Clearance and Glioma Development Table of Contents - Global Oncolytic Virus Immunotherapy Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Virus Type, Therapy Type, Cancer Type, Route of Administration, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Virus Type, Therapy Type, Cancer Type, Route of Administration, End User, and Region Impact of New Cancer Therapy Approvals and Clinical Advances Commercialization Trends and Treatment Access Developments Through 2032 Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User Regional Market Share Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Positioning of Approved and Investigational Oncolytic Virus Therapies Investment Opportunities in the Oncolytic Virus Immunotherapy Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Engineered HSV, Adenovirus, Vaccinia Virus, and Other Viral Platforms Investment Opportunities in Combination Therapy with PD-1, PD-L1, and CTLA-4 Checkpoint Inhibitors Opportunities in Melanoma, Glioblastoma, Lung Cancer, Bladder Cancer, Colorectal Cancer, Pancreatic Cancer, and Ovarian Cancer Advanced Viral Engineering, Systemic Delivery, and Scalable Manufacturing Clinical Development, Regulatory Approval, Reimbursement, and Commercialization Opportunities Through 2032 Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Mechanisms of Oncolytic Virus-Mediated Tumor Destruction and Antitumor Immune Activation Role of Genetically Engineered Viruses in Cancer Immunotherapy Clinical Importance of Oncolytic Viruses in Immunotherapy-Resistant Cancers Established Treatments, Investigational Therapies, and Adjacent Viral Gene Therapy Categories Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Market Forecasting Framework (2026–2032) Market Dynamics Key Market Drivers New Regulatory Approvals and Expansion of Commercial Treatment Options Growing Demand for Treatments in Immunotherapy-Resistant Cancers Clinical Advances in Engineered Viral Platforms Growing Interest in Combination Therapy with Immune Checkpoint Inhibitors Expanding Oncology Research and Specialized Cancer Treatment Infrastructure Challenges and Restraints Impacting Growth Need for Confirmatory Clinical Trials Following Accelerated Approval Complexities in Viral Manufacturing, Quality Control, and Scale-Up Reimbursement and Treatment Access Challenges Clinical Uncertainty Across Different Tumor Types and Treatment Protocols Emerging Opportunities for Stakeholders Development of Combination Regimens with Checkpoint Inhibitors Expansion into Lung Cancer, Glioblastoma, and Other Solid Tumors Systemic Viral Delivery for Metastatic and Inaccessible Tumors Next-Generation Immune-Engineered Viral Platforms Impact of Regulatory and Public Health Factors Clinical Efficacy, Durable Responses, and Confirmatory Trial Requirements Manufacturing Capacity, Oncology Center Readiness, and Commercial Adoption Market Developments and Commercialization Trends Through 2032 Global Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type: Herpes Simplex Virus (HSV) Adenovirus Vaccinia Virus Others, Including Reovirus and Additional Viral Platforms Market Analysis by Therapy Type: Monotherapy Combination Therapy Market Analysis by Cancer Type: Melanoma Glioblastoma Lung Cancer Others, Including Bladder, Colorectal, Pancreatic, and Ovarian Cancers Market Analysis by Route of Administration: Intratumoral Administration Intravenous Administration Market Analysis by End User: Hospitals Specialty Cancer Centers Research Institutes Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User FDA-Approved Therapies and Emerging Commercial Opportunities Clinical Trial Infrastructure and Biotechnology Innovation Commercial Adoption, Reimbursement, and Treatment-Center Readiness Country-Level Breakdown: United States Canada Europe Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User Clinical Research Activities and Engineered Viral Therapy Development Regulatory Pathways and Access to Oncolytic Immunotherapies Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User Established Viral Cancer Treatment Pathways and Domestic Biotechnology Innovation Clinical Research, Regulatory Development, and Oncology Investment Country-Level Breakdown: China Japan South Korea India Rest of Asia-Pacific Latin America Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User Oncology Research Partnerships and Specialized Cancer Treatment Capabilities Availability of Advanced Immunotherapy and Treatment Access Trends Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User Investment in Advanced Oncology Infrastructure Access to Specialized Immunotherapy Services and Treatment Centers Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Amgen Replimune Group Inc. CG Oncology Oncolytics Biotech Inc. Genelux Corporation Transgene S.A. Daiichi Sankyo Shanghai Sunway Biotech F. Hoffmann-La Roche Ltd. Bristol Myers Squibb Merck & Co., Inc. AstraZeneca Johnson & Johnson Circio Holding ASA Competitive Landscape and Strategic Insights Benchmarking Based on Viral Platforms, Clinical Evidence, Regulatory Status, Manufacturing Capabilities, and Regional Presence Approved Product Positioning and Investigational Pipeline Assessment Clinical Trial Progress and Confirmatory Study Requirements Combination Therapy and Checkpoint Inhibitor Strategy Analysis Commercial Readiness, Reimbursement, and Treatment Access Analysis Viral Manufacturing, Quality Control, and Scale-Up Capabilities Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Evidence and Regulatory Approval References Market Definitions and Segment Classification Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) Country Coverage and Regional Classification List of Tables Market Size by Virus Type, Therapy Type, Cancer Type, Route of Administration, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Vendors Approved and Investigational Oncolytic Virus Therapies Clinical Development Programs and Combination Treatment Strategies Regulatory Approval, Confirmatory Trial, and Commercialization Analysis Viral Platform Technologies and Cancer Indication Coverage List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Across All Covered Regions Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Virus Type, Therapy Type, Cancer Type, Route of Administration, and End User (2025 vs. 2032) Global Oncolytic Virus Immunotherapy Ecosystem and Value Chain Analysis Clinical Development and Commercialization Trends (2026–2032) Regional Treatment Access and Biotechnology Investment Trends